Source: Eur Respir J 2006; 27: 664-666
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Wells A. U.. Antioxidant therapy in idiopathic pulmonary fibrosis: hope is kindled. Eur Respir J 2006; 27: 664-666

Member's Comments

No comment yet.

Related content which might interest you: Antifibrotic choice in idiopathic pulmonary fibrosis Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF) Year: 2018 Antioxidants and extracorporal detoxication in therapy of idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 336s Year: 2005 Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation Source: Eur Respir J 2012; 40: 794-795 Year: 2012 The therapy of idiopathic pulmonary fibrosis: what is next? Source: Eur Respir Rev, 28 (153) 190021; 10.1183/16000617.0021-2019 Year: 2019 Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis Source: Eur Respir Rev, 28 (153) 190022; 10.1183/16000617.0022-2019 Year: 2019 Comorbidities influence in idiopathic pulmonary fibrosis antifibrotic treatments Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis Year: 2019 Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review Source: Eur Respir Rev, 29 (157) 190158; 10.1183/16000617.0158-2019 Year: 2020 Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 Sildenafil for pulmonary hypertension complicating idiopathic pulmonary fibrosis: a rationale grounded in basic science Source: Eur Respir J 2016; 47:1615-1617 Year: 2016 Current and future therapeutic approaches in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: 693-703 Year: 2005 Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis Source: Eur Respir J 2015; 45: 1434-1445 Year: 2015 Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence? Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Pulse therapy of corticosteroids in idiopathic pulmonary fibrosis Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis Year: 2010